NASDAQ:CPRX
Related posts
Nervous markets await NvidiaA biopharma that develops for rare diseases, such as LEMS for which CPRX's drug has received approval. But this trip costs US$360,000. Only insurance allows CPRX to charge such prices; revenues have been rising. But there's a ceiling, because there are a limited number of people afflicted with this disease. They bought US rights for the drug Fycompa, and bought a company that makes aGamree to treat another rare disease. An analyst believes the latter drug and feels shares can double. However, the firm Oppenheimer said that CPRX didn't need the money, and then the same firm was listed as a co-manager for a recent share offering. Result: shares dropped 15%. Last year, the CEO retired, and the CFO stepped down, so he thought CPRX may be sold, but the offering throws doubt on that. That said, rare disease companies are hot and so CPRX could be taken over. He doesn't like their business model: buying other companies and their drugs instead of developing their own. And their two drugs have patent protection for only a few more years--bad. There are better stocks in this space.
Catalyst Pharmaceuticals is a American stock, trading under the symbol CPRX-Q on the NASDAQ (CPRX). It is usually referred to as NASDAQ:CPRX or CPRX-Q
In the last year, 1 stock analyst published opinions about CPRX-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Catalyst Pharmaceuticals.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Catalyst Pharmaceuticals In the last year. It is a trending stock that is worth watching.
On 2025-07-16, Catalyst Pharmaceuticals (CPRX-Q) stock closed at a price of $20.935.
We continue to like CPRX for good growth and an attractive valuation. We don't think a whole lot has changed here and management continues to execute. The growth rate will likely moderate as some past drugs start to plateau but we think the valuation accounts for a lot of this while the company seeks out another acquisition to drive further growth.
Unlock Premium - Try 5i Free